Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...

Q4 2025 Management View CEO Robert Ford highlighted that 2025 showcased "Abbott's leadership in innovation, disciplined execution and strategic actions taken to position the company for sustainable ...

Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...

Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path. Abbott Labs is ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be reporting earnings this Thursday before market ...

Abbott Lab's stock bucks a broad market selloff, after quarterly profit extends a long streak of beats on the back of strong demand for diabetes products Abbott Laboratories saw a big jump in demand ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories has agreed to discontinue sales of its ...

Abbott Laboratories and Decom will concentrate on competing in the huge market of potential continuous glucose monitor technology and put any patent disputes behind them for 10 years. North ...